BIOMAT Database Logo BIOMAT Database Logo

Liposome-encapsulated doxorubicin (Doxil) and doxorubicin in the treatment of vaccine-associated sarcoma in cats. 2002

Valerie J Poirier, and Douglas H Thamm, and Ilene D Kurzman, and K Ann Jeglum, and Ruthanne Chun, and Joyce E Obradovich, and Maura O'Brien, and Rogers M Fred, and Brenda S Phillips, and David M Vail
Department of Medical Sciences, University of Wisconsin-Madison, School of Veterinary Medicine, Madison, WI 53706, USA.

The purpose of this randomized, multicenter study was to evaluate the toxicity and efficacy of liposome-encapsulated doxorubicin (LED) and doxorubicin (DOX) in the treatment of feline vaccine-associated sarcoma (VAS). Cats were divided according to their disease status into a microscopic arm (no evidence of gross disease) and a macroscopic arm (evidence of gross disease). Each arm was randomized to receive either LED (1-1.5 mg/kg i.v. q3 weeks) or DOX (1 mg/kg i.v. q3 weeks). Thirty-three cats were entered in the macroscopic arm of the study with an overall response rate of 39% (5 complete response and 8 partial response) and a median time to progression of 84 days. Response rates were not different between LED and DOX. Seventy-five cats were entered into the microscopic arm. When compared to a similar historical control population treated with surgery alone, the cats receiving chemotherapy had a prolonged median disease-free interval (388 days versus 93 days). No difference in efficacy was detected between LED and DOX. LED at 1.5 mg/kg induced delayed nephrotoxicosis in 23%, necessitating a decrease in the recommended dosage to 1 mg/kg, and cutaneous toxicosis in 21.7% of treated cats. This study showed that both DOX and LED are efficacious in the treatment of VAS and should be considered in the treatment of this tumor.

UI MeSH Term Description Entries
D008081 Liposomes Artificial, single or multilaminar vesicles (made from lecithins or other lipids) that are used for the delivery of a variety of biological molecules or molecular complexes to cells, for example, drug delivery and gene transfer. They are also used to study membranes and membrane proteins. Niosomes,Transferosomes,Ultradeformable Liposomes,Liposomes, Ultra-deformable,Liposome,Liposome, Ultra-deformable,Liposome, Ultradeformable,Liposomes, Ultra deformable,Liposomes, Ultradeformable,Niosome,Transferosome,Ultra-deformable Liposome,Ultra-deformable Liposomes,Ultradeformable Liposome
D008297 Male Males
D002371 Cat Diseases Diseases of the domestic cat (Felis catus or F. domesticus). This term does not include diseases of the so-called big cats such as CHEETAHS; LIONS; tigers, cougars, panthers, leopards, and other Felidae for which the heading CARNIVORA is used. Feline Diseases,Cat Disease,Disease, Cat,Disease, Feline,Diseases, Cat,Diseases, Feline,Feline Disease
D002415 Cats The domestic cat, Felis catus, of the carnivore family FELIDAE, comprising over 30 different breeds. The domestic cat is descended primarily from the wild cat of Africa and extreme southwestern Asia. Though probably present in towns in Palestine as long ago as 7000 years, actual domestication occurred in Egypt about 4000 years ago. (From Walker's Mammals of the World, 6th ed, p801) Felis catus,Felis domesticus,Domestic Cats,Felis domestica,Felis sylvestris catus,Cat,Cat, Domestic,Cats, Domestic,Domestic Cat
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D005260 Female Females
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D012509 Sarcoma A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant. Sarcoma, Epithelioid,Sarcoma, Soft Tissue,Sarcoma, Spindle Cell,Epithelioid Sarcoma,Epithelioid Sarcomas,Sarcomas,Sarcomas, Epithelioid,Sarcomas, Soft Tissue,Sarcomas, Spindle Cell,Soft Tissue Sarcoma,Soft Tissue Sarcomas,Spindle Cell Sarcoma,Spindle Cell Sarcomas
D012983 Soft Tissue Neoplasms Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc. Neoplasm, Soft Tissue,Neoplasms, Soft Tissue,Soft Tissue Neoplasm

Related Publications

Valerie J Poirier, and Douglas H Thamm, and Ilene D Kurzman, and K Ann Jeglum, and Ruthanne Chun, and Joyce E Obradovich, and Maura O'Brien, and Rogers M Fred, and Brenda S Phillips, and David M Vail
Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy.
April 1995, Cancer,
Valerie J Poirier, and Douglas H Thamm, and Ilene D Kurzman, and K Ann Jeglum, and Ruthanne Chun, and Joyce E Obradovich, and Maura O'Brien, and Rogers M Fred, and Brenda S Phillips, and David M Vail
Liposomal doxorubicin (Doxil): an effective new treatment for Kaposi's sarcoma in AIDS.
January 1994, Clinical oncology (Royal College of Radiologists (Great Britain)),
Valerie J Poirier, and Douglas H Thamm, and Ilene D Kurzman, and K Ann Jeglum, and Ruthanne Chun, and Joyce E Obradovich, and Maura O'Brien, and Rogers M Fred, and Brenda S Phillips, and David M Vail
Clinical studies of liposome-encapsulated doxorubicin.
January 1994, Acta oncologica (Stockholm, Sweden),
Valerie J Poirier, and Douglas H Thamm, and Ilene D Kurzman, and K Ann Jeglum, and Ruthanne Chun, and Joyce E Obradovich, and Maura O'Brien, and Rogers M Fred, and Brenda S Phillips, and David M Vail
Phase I trial of dose-intense liposome-encapsulated doxorubicin in patients with advanced sarcoma.
May 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Valerie J Poirier, and Douglas H Thamm, and Ilene D Kurzman, and K Ann Jeglum, and Ruthanne Chun, and Joyce E Obradovich, and Maura O'Brien, and Rogers M Fred, and Brenda S Phillips, and David M Vail
Phase II trial of pegylated-liposomal doxorubicin (Doxil) in sarcoma.
April 2003, Cancer investigation,
Valerie J Poirier, and Douglas H Thamm, and Ilene D Kurzman, and K Ann Jeglum, and Ruthanne Chun, and Joyce E Obradovich, and Maura O'Brien, and Rogers M Fred, and Brenda S Phillips, and David M Vail
Comparative effects of free doxorubicin, liposome encapsulated doxorubicin and liposome co-encapsulated alendronate and doxorubicin (PLAD) on the tumor immunologic milieu in a mouse fibrosarcoma model.
January 2022, Nanotheranostics,
Valerie J Poirier, and Douglas H Thamm, and Ilene D Kurzman, and K Ann Jeglum, and Ruthanne Chun, and Joyce E Obradovich, and Maura O'Brien, and Rogers M Fred, and Brenda S Phillips, and David M Vail
Treatment of classic Kaposi's sarcoma with liposomal encapsulated doxorubicin.
November 1997, Lancet (London, England),
Valerie J Poirier, and Douglas H Thamm, and Ilene D Kurzman, and K Ann Jeglum, and Ruthanne Chun, and Joyce E Obradovich, and Maura O'Brien, and Rogers M Fred, and Brenda S Phillips, and David M Vail
Potentiation of cytotoxicity of Kaposi's sarcoma related to immunodeficiency syndrome (AIDS) by liposome-encapsulated doxorubicin.
August 1993, AIDS research and human retroviruses,
Valerie J Poirier, and Douglas H Thamm, and Ilene D Kurzman, and K Ann Jeglum, and Ruthanne Chun, and Joyce E Obradovich, and Maura O'Brien, and Rogers M Fred, and Brenda S Phillips, and David M Vail
Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin.
January 1993, Cancer chemotherapy and pharmacology,
Valerie J Poirier, and Douglas H Thamm, and Ilene D Kurzman, and K Ann Jeglum, and Ruthanne Chun, and Joyce E Obradovich, and Maura O'Brien, and Rogers M Fred, and Brenda S Phillips, and David M Vail
Pegylated liposome-encapsulated doxorubicin and cisplatin in the treatment of head and neck xenograft tumours.
January 2000, Cancer chemotherapy and pharmacology,
Copied contents to your clipboard!